(HANDLE) BRUSSELS - The European Medicines Agency (Ema) has started the evaluation of an application for authorization of GlaxoSmithKline for the Covid treatment of adults and adolescents with the monoclonal antibody Xevudy (sotrovimab). It reads in a note from the EMA. The opinion of the EMA could arrive within the next two months. GlaxoSmithKline developed the medicine together with Vir Biotechnology.
BRUSSELS -
The European Medicines Agency (Ema) has started the evaluation of an application for authorization of GlaxoSmithKline for the Covid treatment of adults and adolescents with the monoclonal antibody Xevudy
(sotrovimab).
It reads in a note from the EMA.
The opinion of the EMA could arrive within the next two months.
GlaxoSmithKline developed the medicine together with Vir Biotechnology.